SEATTLE (August 5, 2015) – Etubics Corporation, a privately-held, clinical stage biotechnology company developing an immunotherapy vaccine platform, announced an average survival increase of 11 months in end-stage colorectal cancer patients in Cancer Immunology, Immunotherapy.
The initial phase 1/2 trial evaluated dosing, safety, immunogenicity, and overall survival of patients suffering from metastatic colorectal cancer (mCRC) after being treated with the Etubics Platform targeting CEA(6D), a peptide marker found on colorectal cancer cells. After further review, it was found that the drug produced an overall survival rate of 30% at 18 months post treatment (11 months on average), while reporting no long-term adverse effects. Levels of carcinoembryonic antigen (CEA)-specific cell-mediated immune (CMI) activity increased during treatment and then decreased from their peak values during follow-up in five patients analyzed; evidence that the immunization was directly responsible for the initial increase in immune response.
The Etubics Platform was found to also increase killer T cells, triggering a CMI response in patients immune to Ad5, the most commonly used adenovirus vector and the backbone of the Etubics Platform. Previous historical studies had shown that patients typically rejected Ad5 based vaccines either on an initial dose or subsequent doses due to patient developed immunity to the delivery platform. The Etubics Platform was shown to be stealth-like to the immune system, thus overcoming this immunity to the platform itself.
“In light of these encouraging results, we are excited to test our new treatment platform on a large number of metastatic colorectal cancer patients to show its clinical effectiveness,” said Dr. Balint, a senior scientist at Etubics and lead author of the paper in Cancer Immunology, Immunotherapy.
Etubics Phase 1/2 mCRC trial was funded primarily through support from the National Cancer Institute (NCI). The Company was previously awarded grants for pre-clinical studies of mCRC (Grant#: 1R43CA134063-01) and the Phase 1/2 clinical trials (Contract#: HHSN261200900059C and Grant#: 2R44CA134063-02), as well as a contract from the NCI to manufacture the ETBX-011 product candidate for the next Phase 2b randomized clinical trial slated to be initiated in the first half of 2016 (Contract#: HHSN261201100097C).
About Etubics
Etubics Corporation, based in Seattle, Wash., is a clinical stage bio-pharmaceutical company, which has developed a proprietary platform technology consisting of a next generation Ad5 vector vaccine platform and a manufacturing E.C7 human cell line, collectively the Etubics Platform. Clinical work to date shows that the Etubics Platform overcomes problems associated with existing adenovirus vectors. The Etubics Platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of infectious diseases and cancers. www.etubics.com
Help employers find you! Check out all the jobs and post your resume.
The initial phase 1/2 trial evaluated dosing, safety, immunogenicity, and overall survival of patients suffering from metastatic colorectal cancer (mCRC) after being treated with the Etubics Platform targeting CEA(6D), a peptide marker found on colorectal cancer cells. After further review, it was found that the drug produced an overall survival rate of 30% at 18 months post treatment (11 months on average), while reporting no long-term adverse effects. Levels of carcinoembryonic antigen (CEA)-specific cell-mediated immune (CMI) activity increased during treatment and then decreased from their peak values during follow-up in five patients analyzed; evidence that the immunization was directly responsible for the initial increase in immune response.
The Etubics Platform was found to also increase killer T cells, triggering a CMI response in patients immune to Ad5, the most commonly used adenovirus vector and the backbone of the Etubics Platform. Previous historical studies had shown that patients typically rejected Ad5 based vaccines either on an initial dose or subsequent doses due to patient developed immunity to the delivery platform. The Etubics Platform was shown to be stealth-like to the immune system, thus overcoming this immunity to the platform itself.
“In light of these encouraging results, we are excited to test our new treatment platform on a large number of metastatic colorectal cancer patients to show its clinical effectiveness,” said Dr. Balint, a senior scientist at Etubics and lead author of the paper in Cancer Immunology, Immunotherapy.
Etubics Phase 1/2 mCRC trial was funded primarily through support from the National Cancer Institute (NCI). The Company was previously awarded grants for pre-clinical studies of mCRC (Grant#: 1R43CA134063-01) and the Phase 1/2 clinical trials (Contract#: HHSN261200900059C and Grant#: 2R44CA134063-02), as well as a contract from the NCI to manufacture the ETBX-011 product candidate for the next Phase 2b randomized clinical trial slated to be initiated in the first half of 2016 (Contract#: HHSN261201100097C).
About Etubics
Etubics Corporation, based in Seattle, Wash., is a clinical stage bio-pharmaceutical company, which has developed a proprietary platform technology consisting of a next generation Ad5 vector vaccine platform and a manufacturing E.C7 human cell line, collectively the Etubics Platform. Clinical work to date shows that the Etubics Platform overcomes problems associated with existing adenovirus vectors. The Etubics Platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of infectious diseases and cancers. www.etubics.com
Help employers find you! Check out all the jobs and post your resume.
